Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines (MR+JE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02643433

Recruitment Status : Completed

First Posted : December 31, 2015

Last Update Posted : August 1, 2016

Sponsor:

Collaborators:

Centers for Disease Control and Prevention

Zhejiang Provincial Center for Disease Control and Prevention

Hubei Provincial Center for Disease Control and Prevention

Information provided by (Responsible Party):

Huaqing Wang, Centers for Disease Control and Prevention, China

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 2016
Actual Study Completion Date :	June 2016

Publications:

Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. 2008 Apr 24;26(18):2234-41. doi: 10.1016/j.vaccine.2008.02.042. Epub 2008 Mar 18.

Measles vaccines: WHO position paper. Wkly Epidemiol Rec. 2009 Aug 28;84(35):349-60. English, French.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Li Y, Chu SY, Yue C, Wannemuehler K, Xie S, Zhang F, Wang Y, Zhang Y, Ma R, Li Y, Zuo Z, Rodewald L, Xiao Q, Feng Z, Wang H, An Z. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. Lancet Infect Dis. 2019 Apr;19(4):402-409. doi: 10.1016/S1473-3099(18)30650-9. Epub 2019 Mar 1.

To Top